Profund Advisors’s Day One Biopharmaceuticals DAWN Stock Holding History

Profund Advisors’s Portfolio DAWN Stock Details DAWN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$583K	Sell	27,210 -30,919	-53%	-$436K	0.02%	499
2025 Q4	$542K	Buy	58,129 +30,494	+110%	+$255K	0.02%	534
2025 Q3	$195K	Buy	27,635 +6,685	+32%	+$46K	0.01%	991
2025 Q2	$136K	Sell	20,950 -3,653	-15%	-$25.1K	﹤0.01%	948
2025 Q1	$195K	Sell	24,603 -5,821	-19%	-$62.7K	0.01%	912
2024 Q4	$385K	Buy	30,424 +3,533	+13%	+$49.2K	0.01%	645
2024 Q3	$375K	Sell	26,891 -716	-3%	-$10.2K	0.01%	676
2024 Q2	$380K	Sell	27,607 -3,005	-10%	-$44K	0.01%	590
2024 Q1	$506K	Sell	30,612 -8,205	-21%	-$123K	0.02%	573
2023 Q4	$567K	Sell	38,817 -1,428	-4%	-$17.3K	0.02%	477
2023 Q3	$494K	Sell	40,245 -12,387	-24%	-$162K	0.03%	472
2023 Q2	$628K	Buy	52,632 +17,303	+49%	+$226K	0.03%	433
2023 Q1	$472K	Buy	+35,329	New	+$690K	0.03%	518

Other funds holding DAWN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

Kryger Capital London, United Kingdom $1.41B AUM 86.31% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return

Profund Advisors's DAWN Position: Q1 2026 in Review

Profund Advisors reduced its Day One Biopharmaceuticals (DAWN) stake by 53% in Q1 2026, selling an estimated $436K and leaving 27,210 shares worth $583K. The position accounts for 0.02% of the portfolio, ranked #499.

Profund Advisors first reported a position in DAWN in Q1 2023 and has held it in 13 quarters since. The position peaked at $628K in Q2 2023. 206 funds tracked by Wall St. Rank hold DAWN as of Q1 2026.

Profund Advisors held 27,210 shares of Day One Biopharmaceuticals worth $583K as of Q1 2026.
Profund Advisors sold 30,919 Day One Biopharmaceuticals shares in Q1 2026, an estimated $436K.
Day One Biopharmaceuticals made up 0.02% of Profund Advisors's portfolio in Q1 2026, its #499 holding.
Profund Advisors first reported a position in Day One Biopharmaceuticals in Q1 2023 and has held it in 13 quarters since.
Profund Advisors's Day One Biopharmaceuticals position peaked at $628K in Q2 2023.
206 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q1 2026.

Based on Profund Advisors's 13F filing for Q1 2026, filed 27 Apr 2026.